Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
Private Practice, Mechanicsville, Virginia, USA.
Correspondence to Shailendra Kapoor, Mechanicsville, VA, USA. E-mail: firstname.lastname@example.org
Received 2 May, 2013
Accepted 15 May, 2013
Barillari et al. have reported interesting data in their recent article. Interestingly, recent data suggest that ritonavir may also exert significant antineoplastic effects in other systemic malignancies.
For example, attenuation of tumor growth is seen in mammary malignancies. Cyclin D1 levels are markedly attenuated. Estrogen receptor α levels are also decreased at the same time. The attenuation of phosphorylated Rb levels accompanies the above changes . As a result, there is increased G1 phase arrest within the tumor cells. Akt activity also suffers and is decreased markedly. Similar effects are seen in ovarian malignancies. Increased G1/growth 1 phase arrest is seen in the ovarian cancer cells. It mediates this effect by attenuating Rb phosphorylation. Akt phosphorylation is also downregulated at the same time . These effects are dose-dependent.
A similar benefit has been noted in pulmonary malignancies. It mediates this role by markedly attenuating survivin levels within the tumor cells. Simultaneous poly-ADP-ribose polymerase 1 cleavage enhancement is seen. ‘Signal transducer and activator of transcription protein 3’ activity is also decreased . As a result, it causes G0/G1 phase arrest. Cyclin D1 expression is decreased at the same time. In addition, ritonavir exhibits synergistic activity when administered along with chemotherapeutic agents such as cisplatin and gemcitabine. Simultaneously, c-Src phosphorylation is inhibited. A similar benefit has been noted in renal carcinomas. For example, significant attenuation of tumor growth has been seen when ritonavir is administered with chemotherapeutic agents such as bortezomib. The combination has a synergistic effect in accentuating protein ubiquitination and also decreases histone deacytelase expression markedly . A similar benefit is noted in renal carcinomas when ritonavir is administered along with suberoylanilide hydroxamic acid. This combination exerts its effects by augmenting histone acetylation . Simultaneous accentuation of dephosporylation of Rb is also seen.
The above examples illustrate the significant antineoplastic effects of ritonavir and the need for further studies in this regard.
There are no conflicts of interest.
© 2014 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at AIDS.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection